Topoisomerase I inhibitors
Lurbinectedin + Irinotecan for Cancer
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is testing a new cancer drug, Lurbinectedin, in combination with another cancer drug, irinotecan. The trial will have two parts: first, they will test different doses of the drugs to see what is safe; then, they will expand the trial to include more people.
CAR T-cell Therapy
IL13Ralpha2 CAR T Cells for Advanced Skin Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial tests the safety and best dose of modified immune cells for patients with advanced melanoma or other cancers that have spread. The treatment uses the patient's own T cells, which are changed in a lab to better attack cancer cells. The goal is to see if these modified cells can safely and effectively fight the cancer.
CAR T-cell Therapy
TIL Therapy for Advanced Cancer
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial tests a treatment for advanced cancers that haven't responded to standard treatments. It involves reducing the patient's immune cells, then using their own enhanced immune cells to fight the cancer, supported by a drug that boosts immune activity.
Popular Filters
Trials for Neuroendocrine Tumors Patients
Radiopharmaceutical
[68Ga]Pentixafor for Neuroendocrine Cancer
Recruiting1 awardPhase < 1
Iowa City, Iowa
This trial uses Gallium-68 Pentixafor, an imaging agent for PET scans, to detect high-grade neuroendocrine tumors. It targets specific markers on these tumors and makes them visible on scans. The study aims to see how consistently this agent works across different scans.
[68]Ga-HA-DOTATATE Imaging for Neuroendocrine Tumors
Recruiting2 awardsPhase 1 & 2
Edmonton, Alberta
This trial tests a new type of body scan for patients with certain types of tumors. The scan uses a small amount of radioactive material to highlight tumors by sticking to specific spots on them. It aims to show that this method is safe and more accurate than current scans. The new scan is useful for locating primary tumors in patients with certain types of cancer.
Radioisotope Therapy
Personalized PRRT for Neuroendocrine Tumors
Recruiting3 awardsPhase 2
Quebec City, Quebec
This trial is testing a new way to give a cancer treatment called peptide receptor radionuclide therapy (PRRT). In this new way, the amount of PRRT given to each person will be different and personalized, based on how their body is expected to absorb the therapy. The goal is to maximize the amount of PRRT that gets to the tumor, while minimizing the amount that gets to healthy organs.
Trials for DSNET Patients
Radiopharmaceutical
[68Ga]Pentixafor for Neuroendocrine Cancer
Recruiting1 awardPhase < 1
Iowa City, Iowa
This trial uses Gallium-68 Pentixafor, an imaging agent for PET scans, to detect high-grade neuroendocrine tumors. It targets specific markers on these tumors and makes them visible on scans. The study aims to see how consistently this agent works across different scans.
[68]Ga-HA-DOTATATE Imaging for Neuroendocrine Tumors
Recruiting2 awardsPhase 1 & 2
Edmonton, Alberta
This trial tests a new type of body scan for patients with certain types of tumors. The scan uses a small amount of radioactive material to highlight tumors by sticking to specific spots on them. It aims to show that this method is safe and more accurate than current scans. The new scan is useful for locating primary tumors in patients with certain types of cancer.
Radioisotope Therapy
Personalized PRRT for Neuroendocrine Tumors
Recruiting3 awardsPhase 2
Quebec City, Quebec
This trial is testing a new way to give a cancer treatment called peptide receptor radionuclide therapy (PRRT). In this new way, the amount of PRRT given to each person will be different and personalized, based on how their body is expected to absorb the therapy. The goal is to maximize the amount of PRRT that gets to the tumor, while minimizing the amount that gets to healthy organs.
Trials for Metastatic Patients
Radioisotope Therapy
Lu-DOTATATE for Neuroendocrine Cancer
Recruiting1 award
Hamilton, Ontario
This trial is testing a targeted radiation therapy called Lutetium-177 Octreotate in patients with advanced neuroendocrine tumors that have specific receptors. The treatment aims to deliver radiation directly to the cancer cells to stop their growth. Patients will receive multiple treatment cycles, and their progress will be monitored over time. Lutetium-177 Octreotate was approved by the FDA in January 2018 for treating certain types of neuroendocrine tumors.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Hypoxia-activating Agent
Tirapazamine + Embolization for Liver Cancer
Recruiting1 awardPhase 1 & 2
Orange, California
This trial is testing a new cancer treatment involving two drugs. The first drug is given before the second drug, which is used to block blood flow to the tumor. The treatment will be given to people with liver cancer who are eligible based on their health. The effects of the treatment will be monitored with MRIs.
Tyrosine Kinase Inhibitor
Pembrolizumab + Lenvatinib for Neuroendocrine Prostate Cancer
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial uses a combination of two drugs, lenvatinib and pembrolizumab, to treat patients with cancer that hasn't responded to other treatments. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. The combination received accelerated FDA approval in September 2019 for all patients with advanced endometrial cancer who have disease progression following previous treatments. The treatment cycles last a few weeks and can continue for several months unless there are side effects or other reasons to stop.
Phase 3 Trials
Radiopharmaceutical
68Ga-DOTA-TATE Imaging for Neuroendocrine Cancer
Recruiting2 awardsPhase 3
Sherbrooke, Quebec
This trial is to establish the safety of a new PET radiotracer, 68Ga-DOTA-TATE, for diagnosing neuro-endocrine cancer patients. The trial is prospective, open-label, and single-center with recruitment across Canada. There is no control group.
Peptide Receptor Radionuclide Therapy
PRRT for Neuroendocrine Tumors
Recruiting2 awardsPhase 3
Saint Louis, Missouri
This trial is testing a new treatment that uses a radioactive drug to target and kill specific cancer cells in patients with certain types of neuroendocrine tumors. It aims to see if this method is more effective and safer than current treatments.
Monoclonal Antibodies
Octreotide + Interferon/Bevacizumab for Neuroendocrine Tumors
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is comparing two treatments for neuroendocrine tumors - octreotide acetate with either recombinant interferon alfa-2b or bevacizumab. The goal is to see if octreotide acetate with recombinant interferon alfa-2b is more effective than with bevacizumab.
Trials With No Placebo
Radiopharmaceutical
[68Ga]Pentixafor for Neuroendocrine Cancer
Recruiting1 awardPhase < 1
Iowa City, Iowa
This trial uses Gallium-68 Pentixafor, an imaging agent for PET scans, to detect high-grade neuroendocrine tumors. It targets specific markers on these tumors and makes them visible on scans. The study aims to see how consistently this agent works across different scans.
[68]Ga-HA-DOTATATE Imaging for Neuroendocrine Tumors
Recruiting2 awardsPhase 1 & 2
Edmonton, Alberta
This trial tests a new type of body scan for patients with certain types of tumors. The scan uses a small amount of radioactive material to highlight tumors by sticking to specific spots on them. It aims to show that this method is safe and more accurate than current scans. The new scan is useful for locating primary tumors in patients with certain types of cancer.
Radioisotope Therapy
Personalized PRRT for Neuroendocrine Tumors
Recruiting3 awardsPhase 2
Quebec City, Quebec
This trial is testing a new way to give a cancer treatment called peptide receptor radionuclide therapy (PRRT). In this new way, the amount of PRRT given to each person will be different and personalized, based on how their body is expected to absorb the therapy. The goal is to maximize the amount of PRRT that gets to the tumor, while minimizing the amount that gets to healthy organs.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.